Allarity Therapeutics Inc已获得美国食品药品监督管理局(FDA)的快速通道认定，该认定适用于其药物Stenoparib用于治疗晚期卵巢癌。这一认定将有助于加速该药物的开发和审批流程，为晚期卵巢癌患者提供新的治疗选择。
Allarity Therapeutics Inc已获得美国食品药品监督管理局(FDA)的快速通道认定，该认定适用于其药物Stenoparib用于治疗晚期卵巢癌。这一认定将有助于加速该药物的开发和审批流程，为晚期卵巢癌患者提供新的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.